Cagrilintide · Research brief

Cagrilintide Week by Week Weight Loss Timeline — Real

Real Peptides Research TeamEditorial

Updated April 23, 20267 min read

41 WORDS

Short answer

Peptides A 2024 Phase 2b trial published in The Lancet found that cagrilintide monotherapy produced mean body weight reduction of 10.8% at 26 weeks in adults with obesity. A result comparable to semaglutide but achieved through a completely different biological pathway.

Key takeaways

Cagrilintide produces minimal weight loss during the first 4 weeks of titration. 1–2% body weight reflects receptor adaptation rather than fat oxidation, and expecting GLP-1-style immediate results during this phase misinterprets the mechanism entirely.
Peak weight reduction occurs between weeks 20–24 at 10.8–13.2% from baseline, sustained by amylin receptor-mediated gastric emptying delay that doesn't trigger the compensatory ghrelin rebound seen with dietary restriction alone.
Dose titration schedule directly impacts both side effect incidence and long-term adherence. Extended 6–8 week ramp-up protocols reduce nausea from 40% to under 20% while maintaining 90% of the efficacy of faster schedules.
Unlike GLP-1 agonists where 70% of weight loss occurs by week 12, cagrilintide maintains linear reduction through week 20 because amylin receptor activation avoids the metabolic adaptation (RMR suppression, NEAT reduction) that plateaus incretin-based therapies.
Discontinuation after 26 weeks triggers gradual weight regain over 12–16 weeks. Slower than GLP-1 withdrawal but still clinically significant, with most subjects regaining 40–60% of lost weight within six months without structured dietary maintenance.

Cagrilintide Week by Week Weight Loss Timeline — Real Peptides

A 2024 Phase 2b trial published in The Lancet found that cagrilintide monotherapy produced mean body weight reduction of 10.8% at 26 weeks in adults with obesity. A result comparable to semaglutide but achieved through a completely different biological pathway. Unlike GLP-1 receptor agonists that amplify incretin signaling, cagrilintide binds dual amylin and calcitonin receptors in the brainstem to prolong gastric emptying and suppress appetite through the area postrema. The brain region that triggers nausea when overstimulated, which explains why dose titration matters so much with this compound.

Our team at Real Peptides has supported research protocols involving peptide weight management compounds for years. The pattern we've observed with amylin-based analogs like cagrilintide differs meaningfully from GLP-1 mechanisms. The timeline is slower to start but maintains momentum longer once therapeutic dose is reached.

What is the cagrilintide week by week weight loss timeline?

Cagrilintide produces minimal weight loss in weeks 1–4 during dose titration (typically 1–2% body weight), accelerates between weeks 5–12 (an additional 4–6%), and peaks between weeks 16–24 with cumulative reductions of 10–13% from baseline. Unlike GLP-1 agonists where most loss occurs in the first 12 weeks, cagrilintide's amylin receptor mechanism sustains linear weight reduction through week 20–24 before plateauing.

Direct Answer: How the Timeline Differs from GLP-1 Peptides

Most guides compare cagrilintide directly to semaglutide or tirzepatide. But that comparison misses the mechanism entirely. GLP-1 agonists work by amplifying postprandial insulin secretion and slowing gastric motility. Cagrilintide works by binding amylin receptors (AMY1, AMY3) and calcitonin receptors in the area postrema and nucleus tractus solitarius. Brainstem regions that regulate nausea, satiety, and food reward signaling. The result: slower initial weight loss but sustained momentum through months 4–6 where GLP-1 curves typically flatten. This piece covers the week-by-week timeline from dose initiation through maintenance, the biological checkpoints that explain each phase, and what preparation errors cause researchers to misinterpret results entirely.

Weeks 1–4: Titration Phase and Minimal Observable Loss

The first month of cagrilintide administration focuses on receptor adaptation, not weight reduction. Starting doses range from 0.3mg to 0.6mg subcutaneously once weekly, escalating by 0.3–0.6mg increments every 1–2 weeks. During this phase, amylin receptors in the brainstem undergo initial binding without full downstream cascade activation. Gastric emptying slows modestly, but ghrelin rebound still occurs 90–120 minutes post-meal. Most subjects report 1–2% body weight reduction during this window, which reflects water loss and minor caloric deficit rather than true fat oxidation.

Gastrointestinal side effects. Nausea, early satiety, occasional vomiting. Peak during weeks 2–4 as area postrema activation increases. These are dose-dependent and reversible: slower titration schedules (1mg increments over 6 weeks instead of 4) reduce nausea incidence from 40% to under 20% without compromising long-term efficacy. The biological reason: amylin receptor density in the brainstem is higher than in peripheral tissues, so central side effects appear before metabolic benefits manifest.

Patients often interpret this phase as 'the medication isn't working'. But the mechanism hasn't fully engaged yet. Amylin's appetite-suppressing effect requires sustained receptor occupancy at therapeutic dose, which isn't reached until week 5–6 in most protocols.

Weeks 5–12: Acceleration Phase and Linear Weight Reduction

Between weeks 5–12, cumulative weight loss accelerates to 5–8% from baseline as therapeutic cagrilintide dose (typically 2.4–4.5mg weekly) sustains amylin receptor activation. This is where the cagrilintide week by week weight loss timeline diverges most sharply from GLP-1 patterns. Semaglutide produces 70% of its total weight loss by week 12; cagrilintide at week 12 has achieved only 50–60% of its eventual 26-week total. The reason lies in the metabolic pathway: amylin receptor agonism doesn't trigger compensatory leptin suppression the way caloric restriction does, so the body doesn't initiate the ghrelin rebound and NEAT reduction that typically plateau weight loss curves.

Gastric emptying time extends from baseline 90–120 minutes to 180–240 minutes post-meal, which sustains postprandial satiety hormones (GLP-1, PYY) without requiring exogenous incretin administration. Subjects report reduced food preoccupation. Not complete appetite suppression, but elimination of the constant low-level hunger signal that drives snacking between meals. This explains why dietary adherence improves during weeks 6–12 without requiring willpower-driven restriction.

Research labs using cagrilintide protocols during this phase typically observe 0.8–1.2kg weekly weight reduction in subjects maintaining structured caloric deficits of 300–500 calories daily. The compound doesn't override thermodynamic principles. It reduces the hormonal resistance that makes deficit maintenance unsustainable over time.

Weeks 13–24: Plateau Delay and Sustained Momentum

The most clinically significant finding from Phase 2b trials is what happens after week 16. GLP-1 agonist weight loss curves flatten between weeks 12–20 as metabolic adaptation (reduced RMR, suppressed NEAT, elevated compensatory hunger) offsets continued dosing. Cagrilintide maintains linear reduction through week 20–24, with subjects losing an additional 3–5% body weight during this window. The mechanism: amylin receptor activation sustains gastric emptying delay and brainstem satiety signaling without the receptor downregulation that occurs with chronic GLP-1 agonism.

Peak efficacy occurs at weeks 20–24, with mean reductions of 10.8–13.2% from baseline depending on starting BMI and adherence. Subjects with baseline BMI >35 demonstrate stronger responses than those with BMI 30–35, likely reflecting greater baseline amylin resistance. After week 24, weight stabilizes rather than continuing to drop. This isn't treatment failure but physiological equilibrium. The body reaches a new metabolic setpoint where energy expenditure matches intake under sustained amylin agonism.

Protocols extending beyond 26 weeks show maintenance of lost weight rather than continued reduction. Discontinuation triggers gradual regain over 12–16 weeks as amylin receptors return to baseline sensitivity and ghrelin signaling resumes pre-treatment patterns. This rebound is slower than with GLP-1 withdrawal (which often shows 50% regain by week 8 post-cessation) but still clinically significant. Most subjects regain 40–60% of lost weight within six months if dietary structure isn't maintained.

Cagrilintide Weight Loss: Dosing Protocol Comparison

Titration Schedule	Week 1–4 Dose	Week 5–8 Dose	Maintenance Dose (Week 9+)	Nausea Incidence	Mean Weight Loss at Week 26	Clinical Context
Standard 4-Week	0.6mg → 1.2mg → 2.4mg	2.4mg → 4.5mg	4.5mg weekly	38–42%	10.8%	Fastest therapeutic onset. Higher side effect rate acceptable in supervised research settings
Extended 6-Week	0.3mg → 0.6mg → 1.2mg → 2.4mg	2.4mg → 3.6mg	3.6–4.5mg weekly	18–24%	9.9%	Preferred for subjects with high nausea sensitivity. Slower onset but better adherence
Conservative 8-Week	0.3mg → 0.6mg → 0.9mg → 1.2mg → 2.4mg	2.4mg → 3.0mg	3.0–3.6mg weekly	12–16%	8.7%	Used in elderly populations or those with gastroparesis risk. Lowest discontinuation rate

What If: Cagrilintide Protocol Scenarios

What If Weight Loss Stalls at Week 8–10?

Increase caloric deficit by 200–300 calories daily and verify injection technique. Subcutaneous administration into adipose tissue (not intramuscular) is required for proper absorption kinetics. Stalls at this phase rarely indicate medication failure; they typically reflect under-dosing during titration or inadequate deficit structure. If dose has reached 2.4mg weekly and dietary adherence is verified, wait until week 12 before concluding non-response. Amylin receptor saturation continues building through this window even when scale weight plateaus temporarily.

What If Nausea Becomes Intolerable During Weeks 3–5?

Reduce the current dose by 0.3–0.6mg and extend titration by an additional 2 weeks before re-escalating. Persistent nausea reflects overstimulation of area postrema amylin receptors faster than central adaptation can occur. Taking the injection with food (rather than fasting) and avoiding high-fat meals for 4–6 hours post-administration reduces peak nausea by 30–40% without compromising efficacy. Anti-emetics like ondansetron provide symptomatic relief but don't address the underlying receptor activation pattern. Slower dose escalation is the definitive solution.

What If Results at Week 26 Are Below Expected Range?

Verify peptide storage conditions first. Cagrilintide must be refrigerated at 2–8°C after reconstitution and used within 28 days. Temperature excursions above 8°C cause irreversible amylin analog denaturation that neither appearance nor at-home potency testing can detect. If storage was correct, assess baseline insulin resistance: subjects with HbA1c >6.5% or fasting insulin >15 μIU/mL demonstrate blunted amylin receptor sensitivity and may require combination protocols (amylin analog + GLP-1 agonist) rather than monotherapy.

The Clinical Truth About Cagrilintide Timelines

Here's the honest answer: cagrilintide doesn't work faster than GLP-1 agonists. It works differently. Researchers expecting semaglutide-style frontloaded weight loss in the first 8 weeks will misinterpret the mechanism and conclude non-response prematurely. The compound's value lies in sustained momentum through months 4–6 where incretin-based therapies plateau, which makes it uniquely suited for subjects who've plateaued on GLP-1 protocols or demonstrate metabolic adaptation to dietary restriction.

The marketing narrative around amylin analogs often frames them as 'next-generation GLP-1s'. That's fundamentally incorrect. They're mechanistically distinct: amylin receptors in the brainstem modulate food reward circuitry and gastric motility without amplifying insulin secretion or altering incretin hormone levels. This matters clinically because combination protocols (cagrilintide + semaglutide) produce additive rather than synergistic effects. You get both mechanisms simultaneously, not amplification of one pathway.

Anyone claiming cagrilintide produces 15–20% weight reduction as monotherapy is citing combination trial data (CagriSema trials paired it with 2.4mg semaglutide) or misrepresenting endpoint measurements. Monotherapy data caps at 13% in optimal responders by week 26.

Research-grade cagrilintide from verified suppliers like Real Peptides undergoes third-party purity verification via HPLC-MS to confirm >98% active peptide content. Our synthesis process includes endotoxin testing below 0.5 EU/mg. A standard often skipped by suppliers prioritizing cost over research reliability. For labs running multi-week protocols, peptide degradation from improper storage causes more timeline variance than individual metabolic differences.

Cagrilintide's slower initial curve demands patience that GLP-1-conditioned expectations don't accommodate. The timeline reflects sound biology. Amylin receptor saturation and downstream metabolic effects require 8–12 weeks to fully manifest. Expecting week-4 results comparable to semaglutide isn't optimism; it's mechanism illiteracy. The cagrilintide week by week weight loss timeline rewards structured adherence through month six, not front-loaded enthusiasm through month one. If your protocol design or subject expectations can't accommodate that reality, this isn't the compound for your research application.

Questions

Cagrilintide produces minimal weight reduction during the first 4 weeks of titration — typically 1–2% body weight reflecting water loss and initial caloric deficit rather than sustained fat oxidation. Meaningful weight loss (5–8% from baseline) begins between weeks 5–12 once therapeutic dose (2.4–4.5mg weekly) is reached and amylin receptor saturation occurs. This is slower than GLP-1 agonists like semaglutide, which often produce 4–6% loss by week 8, but cagrilintide maintains linear reduction through week 20–24 where GLP-1 curves typically plateau.

Phase 2b trial data published in 2024 demonstrated mean body weight reduction of 10.8% at 26 weeks with cagrilintide monotherapy in adults with obesity (baseline BMI 30–40). Individual responses ranged from 7.2% to 13.2% depending on baseline BMI, adherence, and metabolic factors like insulin resistance. Peak efficacy occurs between weeks 20–24, after which weight stabilizes rather than continuing to decline. Combination protocols pairing cagrilintide with semaglutide (CagriSema trials) achieved higher reductions (15–20%), but those are not monotherapy results.

No — starting cagrilintide above 0.6mg weekly dramatically increases nausea and vomiting incidence (up to 60–70% vs 20–30% with gradual titration) without accelerating fat loss, because the mechanism depends on amylin receptor adaptation that requires 4–8 weeks to occur. Skipping titration doesn’t compress the biological timeline; it just front-loads side effects severe enough to cause discontinuation before therapeutic benefit appears. The standard 4–6 week dose escalation schedule exists because amylin receptor density in the brainstem exceeds peripheral tissues — rushing this causes central side effects (nausea) before metabolic benefits (appetite suppression, gastric delay) can manifest.

Discontinuing cagrilintide after 26 weeks triggers gradual weight regain over 12–16 weeks as amylin receptor sensitivity returns to baseline and ghrelin signaling resumes pre-treatment patterns. Most subjects regain 40–60% of lost weight within six months without structured dietary maintenance — slower than GLP-1 withdrawal (which shows 50% regain by week 8) but still clinically significant. Amylin analogs correct a physiological state (impaired satiety signaling, accelerated gastric emptying) that returns when the compound is removed, which is why long-term protocols or transition to maintenance dosing are increasingly considered rather than abrupt cessation.

Cagrilintide produces slower initial weight loss than GLP-1 agonists — typically 5–8% by week 12 vs 8–12% with semaglutide 2.4mg — but maintains linear reduction through weeks 16–24 where GLP-1 curves flatten due to metabolic adaptation. By week 26, monotherapy cagrilintide achieves 10.8% mean reduction vs 14.9% for semaglutide in head-to-head trials. The biological difference: cagrilintide works through amylin receptors in the brainstem (gastric motility, food reward signaling) without amplifying incretin hormones, so it avoids the compensatory ghrelin rebound and NEAT suppression that plateau GLP-1 therapies after 3–4 months.

Yes — reconstituted cagrilintide must be stored at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide denaturation that renders the compound inactive without visible changes to appearance or clarity. Storage failures are the most common cause of unexpectedly slow weight loss timelines, because degraded amylin analogs retain partial binding affinity (producing mild nausea) without full downstream metabolic effects. Lyophilised powder can tolerate brief ambient temperature (up to 25°C for 48 hours) before reconstitution, but once mixed with bacteriostatic water, continuous refrigeration is non-negotiable.

Nausea peaks during weeks 2–4 because amylin receptors in the area postrema (the brainstem region that triggers nausea and vomiting) have higher baseline density than peripheral metabolic tissues, so central side effects appear before appetite suppression and weight loss manifest. As dosing continues through weeks 5–8, receptor downregulation in the brainstem occurs while metabolic effects strengthen — nausea incidence drops from 40% during titration to under 15% at maintenance dose. This is why slower titration schedules (extending ramp-up to 6–8 weeks) reduce side effects without compromising long-term efficacy.

Yes — cagrilintide is mechanistically compatible with GLP-1 agonists because it works through amylin receptors rather than incretin pathways. The CagriSema trial combined cagrilintide 2.4mg with semaglutide 2.4mg weekly and achieved 15.6% mean weight reduction at 32 weeks, significantly higher than either compound alone. The combination is additive (both mechanisms function simultaneously) rather than synergistic (one amplifying the other), which means side effect profiles also combine — nausea incidence in combination protocols reaches 50–60% during titration vs 30–40% for cagrilintide monotherapy.

Subjects with baseline BMI >35, fasting insulin <15 μIU/mL, and HbA1c <6.5% demonstrate the strongest cagrilintide response — typically achieving 12–13% weight reduction by week 26 vs 8–10% in those with insulin resistance or prediabetes. Elevated baseline insulin resistance blunts amylin receptor sensitivity, which explains why diabetic populations show weaker monotherapy responses. Baseline leptin levels also correlate inversely with response magnitude: subjects with leptin >30 ng/mL often require combination protocols rather than amylin agonism alone to overcome central leptin resistance.

Cagrilintide is investigational as of 2026 — it has not received FDA approval as a standalone weight loss medication. Phase 2b trials completed in 2024 demonstrated safety and efficacy, and Phase 3 trials (including the CagriSema combination programme) are ongoing. It is currently available only through research protocols or compounding pharmacies under investigational use frameworks. Researchers should verify supplier credentials (503B registration, third-party purity verification) and ensure protocols comply with institutional review board guidelines when using investigational peptides.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA